The atypical antipsychotic cariprazine, marketed as Vraylar, has gained FDA approval for treating schizophrenia and bipolar disorder in adults.
“It is important to have a variety of treatment options available to patients with mental illnesses so that treatment plans can be tailored to meet a patient’s individual needs,” Mitchell Mathis, MD, director of the division of psychiatry products in the FDA’s Center for Drug Evaluation and Research, said in a statement (http://1.usa.gov/1LjZEgw).
Voelker R. New Atypical Antipsychotic. JAMA. 2015;314(17):1789. doi:10.1001/jama.2015.14005